Itacitinib - Incyte Corporation
Alternative Names: IBI-377; INCB-039110; INCB-039110-adipate; INCB-39110; Itacitinib-adipateLatest Information Update: 22 Jul 2024
At a glance
- Originator Incyte Corporation
- Developer ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP); AstraZeneca; H. Lee Moffitt Cancer Center and Research Institute; Incyte Corporation; Innovent Biologics; National Cancer Institute (USA); University of Utah
- Class Acetonitriles; Anti-inflammatories; Antianaemics; Antibronchitics; Antineoplastics; Antipsoriatics; Antirheumatics; Azetidines; Fluorocarbons; Piperidines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
- Mechanism of Action Janus kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cytokine release syndrome; Diffuse large B cell lymphoma; Diffuse scleroderma; Haematological malignancies; Haemophagocytic lymphohistiocytosis; Hodgkin's disease; Immunological disorders; Myelofibrosis; Non-small cell lung cancer; Solid tumours
- Phase I/II Bronchiolitis obliterans; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
- Phase I Graft-versus-host disease; T-cell prolymphocytic leukaemia
- No development reported Aplastic anaemia; Liver cancer; Malignant melanoma; Soft tissue sarcoma
- Discontinued Pancreatic cancer; Plaque psoriasis; Rheumatoid arthritis
Most Recent Events
- 26 May 2024 Incyte Corporation completes the phase I clinical trials in Graft-versus-host disease (Prevention) in USA (PO) (NCT03755414)
- 08 May 2024 Fred Hutchinson Cancer Research Center and Incyte Corporation terminate a phase I trial in Soft tissue sarcoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO), due to slow enrollment in the last remaining cohort and a lack of evidence of clinical benefit (NCT03670069)
- 09 Dec 2023 Updated adverse events data from the phase II trial for Cytokine release syndrome presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)